⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823074 | 1.00 | — | — | |
| SCHEMBL20456853 | 0.81 | — | — | |
| SCHEMBL28525698 | 0.79 | CFTR (0.38) | — | |
| SCHEMBL13086010 | 0.77 | — | — | |
| SCHEMBL21240970 | 0.75 | — | — | |
| SCHEMBL29699358 | 0.75 | — | — | |
| SCHEMBL2016623 | 0.75 | — | — | |
| SCHEMBL15759816 | 0.75 | — | — | |
| SCHEMBL5019591 | 0.75 | — | — | |
| SCHEMBL594059 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612413-B2 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-12435090-B2 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use | REPARE THERAPEUTICS INC. (CA) | 2025-10-07 | — | — | US | disclosed |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250236609-A1 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-07-24 | — | — | US | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-1546117-A2 | PROTEIN KINASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040106615-A1 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-03 | — | — | US | disclosed |
| CN-1487924-A | Farnesyl transferase inhibitors | ���Ͽع�����˾ | 2004-04-07 | — | — | CN | disclosed |
| WO-2004016597-A2 | PROTEIN KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1339695-A1 | FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002074747-A1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |